Compare CREV & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CREV | CDT |
|---|---|---|
| Founded | 2007 | 2019 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1M | 2.9M |
| IPO Year | N/A | N/A |
| Metric | CREV | CDT |
|---|---|---|
| Price | $2.53 | $1.43 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 141.7K | ★ 388.8K |
| Earning Date | 01-30-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $47,677,475.00 | N/A |
| Revenue This Year | $40.32 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 86.77 | N/A |
| 52 Week Low | $1.48 | $1.43 |
| 52 Week High | $9.45 | $2,198.40 |
| Indicator | CREV | CDT |
|---|---|---|
| Relative Strength Index (RSI) | 56.65 | 36.47 |
| Support Level | $1.57 | $1.61 |
| Resistance Level | $1.77 | $1.75 |
| Average True Range (ATR) | 0.30 | 0.16 |
| MACD | 0.12 | -0.01 |
| Stochastic Oscillator | 69.96 | 0.55 |
Carbon Revolution PLC is an Australian-based technology company manufacturing carbon fiber wheels. It is an OEM supplier and a world-wide manufacturer of lightweight technology carbon fibre wheels to the automotive industry. The Company supplies wheels to OEMs across the globe for luxury and high-performance vehicles and SUVs, and is developing wheels for electric vehicles under contract for its OEM customers. The company generates maximum revenue Internationally.
CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.